Schiavetto Ilaria

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Domenica Lorusso

Agostino Gemelli University Polyclinic

De Giorgi Ugo

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

P De Domenico

Vita-Salute San Raffaele University

Gallo Ciro

University of Campania "Luigi Vanvitelli"

Davide Lombardi

Centro di Riferimento Oncologico

Cecere Sabrina Chiara

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Clorinda Schettino

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Zafarana Elena

Hospital of Prato

Arenare Laura

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

DDe Angelis Carmine

University Hospital of Basel

Cooperative Institutions

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Istituti di Ricovero e Cura a Carattere Scientifico

Fondazione IRCCS Istituto Nazionale dei Tumori

University of Campania "Luigi Vanvitelli"

European Institute of Oncology

Istituto di Ematologia di Bologna

Università Cattolica del Sacro Cuore

University of Naples Federico II

Agostino Gemelli University Polyclinic

Centro di Riferimento Oncologico

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study

International Journal of Gynecological Cancer (2019)

Elisa Tripodi Cormio Gennaro De Giorgi Ugo V. Scagliotti Giorgio R Daniela

Background

Pegylated liposomal doxorubicin (PLD) is an active and well-tolerable treatment in ovarian cancer relapse, either alone or in combination with other drugs. No data are available on the possibility to rechallenge PLD treatment in long survivor patients with recurrent ovarian cancer, as evaluated for platinum agent, paclitaxel and gemcitabine. The aim of the present study was to evaluate the anti-tumor activity and the toxicity profile of re-challenge of PLD in recurrent ovarian cancer patients.

Methods

Data on 27 patients with epithelial ovarian cancer treated in the last ten years (2007-2017) with palliative PLD rechallenge were included in this multicenter retrospective Italian study.

Results

The objective response rate to PLD re-treatment were complete response in 19%, partial response in 30% and stable disease in 37%. Only 1 case of G4 hematological toxicity was reported. No patient experienced severe cardiac impairment (G2-4).

Conclusion

PLD rechallenge represents an active and safe possibility of treatment for long survivor ovarian cancer patients.

10.1136/ijgc-2018-000034

Cite

Citations (1)

MITO END-3: A randomized phase II trial of avelumab plus carboplatin and paclitaxel compared to carboplatin and paclitaxel in advanced or recurrent endometrial cancer.

Zenodo (CERN European Organization for Nuclear Research) (2022)

Pignata Sandro Giovanni Scambia Clorinda Schettino Arenare Laura Pisano Carmela

Adding checkpoint inhibitors to first-line chemotherapy might improve the outcome of advanced/recurrent endometrial cancer (EC) patients. MITO END3 is a randomized phase II trial comparing avelumab plus carboplatin/paclitaxel versus carboplatin/paclitaxel in patients with advanced/recurrent EC and ECOG performance status 0-1. Primary endpoint was progression-free survival (PFS); superiority of the experimental arm was tested with 80% power and one-tailed alpha 0·20; subgroup analyses according to mismatch repair (MMR) status were planned. ClinicalTrials.gov NCT03503786.

Carboplatin

Avelumab

10.5281/zenodo.7254191

Cite

Citations (0)

Retrospective Analysis of Familial Clustering for Malignant Melanoma

Melanoma Research (2004)

Cristiane M. Ida Schiavetto Ilaria Paula Matilde Sara Pepe Fatigante Gabriella

Background Malignant Melanoma (MM) is familial in 5–7% of cases. Germline mutations of the CDKN2 and CDK4 genes are involved in the pathogenesis of hereditary MM, but the high frequency of familial clustering suggests other genes involved. MM seems to cluster with hereditary syndrome such as Hereditary Breast/Ovarian Cancer (HBOC). In this respect, some authors reported that carriers of BRCA 2 germline mutations have a significantly increased risk for MM (RR: 2.58). AIMS We investigate family history of MM patients to define the familial clustering for MM and history for other tumours. Methods We retrospectively analysed family history of 342 consecutive MM cases referred from 1994 to 2002 to the “Gruppo Melanoma”, Azienda Universitaria Policlinico, University “Federico II” of Naples. We divided the cases into four subsets: 1) multiple MM; 2) MM aggregated with other tumours in the proband; 3) MM with a family history of MM; and 4) MM with a family history of other tumours. We collected the pedigree, after informed consent, in all cases with a family history of MM or other tumours. Results Data analysis showed: multiple MM in 5/342 cases (1.46%); MM aggregated with other tumours in the proband in 10/342 cases (2.9%); MM with a family history of MM in 13/342 cases (3.8%) and MM with a family history of other tumours in 28/342 cases (8.2%). We propose pedigree construction to 41 subjects: we collected 23 pedigrees, 14 pedigree are ongoing, while 4 cases refused their consent. Conclusion Patient affected by Malignant Melanoma seems to be at increased risk to develop other tumours and healthy individuals belonging to families with a high clustering for malignant melanoma and other tumours could be at risk for cancers. Supported by MIUR-COFIN 2001.

Proband

Pedigree chart

10.1097/00008390-200404000-00044

Cite

Citations (0)

MITO END-3: A randomized phase II trial of avelumab plus carboplatin and paclitaxel compared to carboplatin and paclitaxel in advanced or recurrent endometrial cancer.

Zenodo (CERN European Organization for Nuclear Research) (2022)

Pignata Sandro Giovanni Scambia Clorinda Schettino Arenare Laura Pisano Carmela

Carboplatin

Avelumab

10.5281/zenodo.7254190

Cite

Citations (0)